Beneficial effect of combination therapy using an angiotensin-converting enzyme inhibitor plus verapamil on circulating resistin levels in hypertensive patients with type 2 diabetes

• Published in: Experimental and clinical cardiology Vol. 17; no. 4; pp. 202 - 204
• Main Authors: Rubio-Guerra, Alberto F, Vargas-Robles, Hilda, Lozano Nuevo, Jose J, Elizalde-Barrera, Cesar I, Huerta-Ramirez, Saul, Escalante-Acosta, Bruno A
• Format: Journal Article
• Language: English
• Published: Canada Pulsus Group Inc 01-01-2012
• Subjects: Clinical Cardiology: Original; Verapamil; Diabetes; Fixed-dose combination; Trandolapril; Resistin
• ISSN: 1205-6626; 1918-1515

Resistin levels are strongly correlated with insulin resistance and vascular inflammation. Type 2 diabetic and hypertensive patients have higher circulating levels of resistin, which is associated with endothelial dysfunction.
To compare the effect of trandolapril (T) and its fixed-dose combination with verapamil (FDTV) on resistin levels in hypertensive, type-2 diabetic patients.
Forty type-2 diabetic patients with never-treated hypertension were randomly assigned to two groups. One group received FDTV 2 mg/180 mg once per day; the other group received T 2 mg once per day. Study drugs were administered for three months in both groups. Resistin levels were measured using ELISA at the beginning of the study and at study end. Patients were evaluated monthly for blood pressure, fasting serum glucose levels and adverse events. Statistical analysis was performed using ANOVA.
All patients experienced a significant reduction in blood pressure. Both therapeutic regimens reduced resistin levels; however, FDTV treatment resulted in a greater decrease in resistin levels (mean [± SD] 25.5±13 ng/mL to 17.2±10 ng/mL) when compared with T treatment (22.4±12 ng/mL to 18.5±8 ng/mL) (P<0.05). None of the patients experienced an adverse event.
Results showed that FDTV resulted in a greater reduction in resistin levels than T treatment alone.